Nanolynx Biologics AG
Conditionally active nanobody-drug conjugates (Smart NDCs)
Nanolynx Biologics is developing first- and best-in-class conditionally active nanobody-drug conjugates (CA-NDCs) engineered for tumor-selective target binding, delivering precision therapies with superior safety and efficacy. Our Intellibody" platform transforms nanobodies to overcome the key limitations of conventional antibody-drug conjugates (ADCs), systemic toxicity and poor tumor tissue penetration, unlocking new treatment options for patients with hard-to-treat solid tumors.
Co-founders: Georg Rüedi, Jean-Philippe Bürckert, Maurice Brozzo
Innovation: Our platform enables an unprecedented approach, combining tumor-selective activation with enhanced tumor penetration.
Market: Our CA-NDCs address hard-to-treat solid tumors, exceeding an estimated market of $10B globally.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
No news
No milestones
No Jobs
No videos and documents
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
Nanolynx Biologics AG
Conditionally active nanobody-drug conjugates (Smart NDCs)
Website:
www.linkedin.com/company/nanolynx-biologics/
Headquarter:
Allschwil
Foundation Date:
December 2025
Technology:
- Biotech
Sectors:
- Biotech
- Cancer
- Drug development platforms
- Drug discovery
- Machine Learning / AI
- Research and development
- Protein drugs
Support received
